New Treatment Approved for Chronic Hepatitis C Genotype 3 Infections

Article

The US Food and Drug Administration (FDA) today approved daclatasvir (Daklinza/ Bristol-Myers Squibb) for use with sofosbuvir for the treatment of hepatitis C virus (HCV) genotype 3 infections.

The US Food and Drug Administration (FDA) today approved daclatasvir (Daklinza/ Bristol-Myers Squibb) for use with sofosbuvir for the treatment of hepatitis C virus (HCV) genotype 3 infections.

To measure whether an individual’s hepatitis C virus could no longer be detected in the bloodstream 12 weeks post-treatment, researchers conducted a clinical trial that evaluated 152 treatment-naïve and treatment-experienced individuals suffering from chronic HCV genotype 3 infection.

Participants were administered Daklinza 60 mg and sofosbuvir 400 mg once daily for 12 weeks and were also monitored for 24 weeks following the end of treatment.

Results indicated 98% of treatment-naïve participants without liver cirrhosis and 58% of the treatment-naïve participants with cirrhosis achieved sustained virologic response at 12 weeks.

For the treatment-experienced group, 92% without liver cirrhosis and 69% with cirrhosis achieved sustained virologic response at 12 weeks.

The most common adverse events reported during testing were fatigue and headache. The Daklinza label will include a warning that some patients may be at risk for symptomatic bradycardia when amiodarone is co-administered with sofosbuvir in combination with another HVC direct-acting antiviral, including Daklinza.

Daklinza is the first drug that can safely and effectively treat genotype 3 HCV without the use of concomitant interferon or ribavirin.

Edward Cox, MD, director of the Office of Antimicrobial Products in the FDA

S Center for Drug Evaluation and Research, remarked, “Today’s approval provides a new option for patients with genotype 3 HCV, including those patients who cannot tolerate ribavirin.”

Related Videos
Stephen Congly, MD | Credit: University of Calgary
Unmet Needs in HBV Thumbnail featuring Nancy Reau, MD, Andrew Talal, MD, and Chari Cohen, DrPH, MPH
Unmet Needs in HBV Thumbnail featuring Nancy Reau, MD, Andrew Talal, MD, and Chari Cohen, DrPH, MPH
Unmet Needs in HBV Thumbnail featuring Nancy Reau, MD, Andrew Talal, MD, and Chari Cohen, DrPH, MPH
Unmet Needs in HBV Thumbnail featuring Nancy Reau, MD, Andrew Talal, MD, and Chari Cohen, DrPH, MPH
Unmet Needs in HBV Thumbnail featuring Nancy Reau, MD, Andrew Talal, MD, and Chari Cohen, DrPH, MPH
Unmet Needs in HBV Thumbnail featuring Nancy Reau, MD, Andrew Talal, MD, and Chari Cohen, DrPH, MPH
Andrew Talal, MD | Credit: University at Buffalo
Andrew Talal, MD | Credit: University at Buffalo
Megan Rose Curtis, MD | Credit: Megan Rose Curtis on LinkedIn
© 2024 MJH Life Sciences

All rights reserved.